MA

Mark Angelino

Stealth at newco

Greater Boston

Overview

Work Experience

  • 2023 - Current

  • Innovation and Technology Advisory group (ITAG)

    2022

    CCRM is a not-for-profit, public-private consortium supporting the development of foundational technologies that accelerate the commercialization of cell and gene therapies, and regenerative medicine technologies.

  • Independent Board Member

    2021

  • Venture Partner

    2021 - 2023

    - CGT: company creation (2), series A (Cargo Tx)

  • Chief Operating Officer and founder

    2016 - 2021

  • SVP, Pharmaceutical Sciences

    2012 - 2016

    - Member of Leadership Team - Responsible for development, manufacturing, and operations; franchise lead for rare diseases - Skysona, Zynteglo, Abecma, and Lyfgenia

  • Sr. Director, Research and Development; Site Head-Cambridge

    2008 - 2012

    - Lead all R&D (res., cmc, dmpk, tox, quality) and Operation functions for the Cambridge, MA site - Transferred with the acquisition of Archemix hemophilia assets - Led diligence for gene therapy assets (resulted in Chatham Tx acquisition)

  • Senior Director, Process Development and Manufacturing

    2007 - 2008

    - Managed validation and regulatory responses for enoxaparin (Lovenox) ANDA approval. - Lead dev. & manufacturing for glatiramir acetate (Copaxone) ANDA. Primary author on ANDA.

  • Associate Director, Process Development

    2002 - 2006

Relevant Websites